Significance of immune response to enzyme-replacement therapy for patients with a lysosomal storage disorder

This publication has 12 references indexed in Scilit:

• Immune tolerance after long-term enzyme-replacement therapy among patients who have mucopolysaccharidosis I
  The Lancet, 2003
• Safety and Efficacy of Recombinant Human α-Galactosidase A Replacement Therapy in Fabry's Disease
  New England Journal of Medicine, 2001
• Recombinant human acid ??-glucosidase enzyme therapy for infantile glycogen storage disease type II: Results of a phase I/II clinical trial
  Genetics in Medicine, 2001
• Enzyme Replacement Therapy in Mucopolysaccharidosis I: Altered Distribution and Targeting of α-l-Iduronidase in Immunized Rats
  Molecular Genetics and Metabolism, 2000
• Immune Response to Enzyme Replacement Therapy in Lysosomal Storage Disorder Patients and Animal Models
  Molecular Genetics and Metabolism, 1999
• Prevalence of Lysosomal Storage Disorders
  JAMA, 1999
• Management of Neutralizing Antibody to Ceredase in a Patient With Type 3 Gaucher Disease
  Published by American Academy of Pediatrics (AAP) ,1997
• Enzyme replacement therapy in Mucopolysaccharidosis VI: evidence for immune responses and altered efficacy of treatment in animal models
  Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1997
• Replacement Therapy for Inherited Enzyme Deficiency
  New England Journal of Medicine, 1974
• α-Glucosidase deficiency in generalized glycogen-storage disease (Pompe's disease)
  Biochemical Journal, 1963